Pharmpur Gmbh

Bausch-lomb Incorporated

Dirk-Henning Menz

Joachim Dresp

Karin Kobuch

Helmut Ritter

Erhard Kemnitz

Udo Gross

Veit-Peter Gabel

Martin Winter

Hans Hoerauf

Bernd Mueller

Klaus Ganser

Bernd MÜLLER

The invention relates to modified polysaccharide ethers having a weight-averaged molecular weight of 40,000 to 500,000 g/mole, zero shear viscosity of more than 10 Pa&#xb7;s, and pseudo-plasticity of more than 20. These modified polysaccharide ethers are obtainable by reacting cellulose-based polysaccharide ether(s) with at least one mesogenic modification agent or modified polysaccharide ethers, obtainable by reacting polysaccharide ether(s) selected from hydroxypropylmethyl cellulose (HPMC), hydroxyethylmethyl cellulose (HEMC), methyl cellulose, and cellulose ethers with methyl and/or ethyl and/or propyl groups and mixtures thereof, with at least one mesogenic modification agent. These substances can be used to produce gel-like to stable aqueous preparations having viscoelastic flow properties, which are suited for use in the human body, particularly within the scope of ophthalmologic procedures.

Water-soluble polysaccharide ethers and their use

The invention relates to a plastically deformable implant for inserting into bodily orifices of the human or animal body. Implants of this type are used, for example, in ophthalmology, in particular, as vitreous body or lens replacements and in dentistry, for example, for filling extraction cavities in jaw-bones. Known implants, however, are not suitable for long-term use. The invention aims to provide a deformable plastic implant which also has a long-term application. This is achieved by the fact that the implant consists of a gel which is not sealed, containing fluorocarbon and which is directly introduced into the natural, or artificially created bodily orifice.

Plastically deformable implant

The invention relates to the utilization of a highly fluorinated oligomeric alkane as a therapeutic agent in ophthalmology, the alkane having the general formula [&#x2014;R(CH)CR&#x2014;CR&#x2014;], wherein Ris a linear or branched perfluorinated alkyl chain CFto CF, Rand Rare independently selected from the group consisting of H, CH, CHand CH, n is selected from the numbers 0, 1 and 2, and x is a number between 2 and 6, with a molar mass of at least 750. According to the invention, a pharmacological agent is provided that is used in ophthalmology and that causes little or no damage to the retina even when used over a long period.

Utilization of a highly fluorinated oligomeric alkane in ophthalmology

A tear replacement solution that contains at least one water-soluble fluorosurfactant, water and a non-polar component, preferably in gel form, and a method for the external treatment for the eye of an mammal by applying the tear replacement solution to the eye, preferably by placing in the conjunctival sac.

Artificial tear replacement solution

The present invention concerns fluorocarbons for use in ophthalmology. Fluorocarbons disclosed in the prior art can only be left in the eye for a limited period of time because they cause damage to the retina or intraocular structure. The present invention provides an oxygen-fluorocarbon mixture having a dissolved oxygen content of less than 6% by volume, which can be used as an ophthalmological agent for longer periods of time than conventional fluorocarbons, with little or no damage to the retina or intraocular structures. The invention also provides a process for preparing the oxygen-fluorocarbon mixture. In one embodiment, up to 20% by volume of a second gas, such as carbon dioxide or nitric oxide, is combined with the oxygen-fluorocarbon mixtures.

Low-oxygen fluorocarbon as an agent for ophthalmology

The invention concerns a partially fluorinated alkane with the general formula R,&lsqb;CF,&mdash;CH,&rsqb;R,, wherein R,is a substituent of the general formula C,H,selected from the group consisting of n-alkyl, sec-alkyl, tert-alkyl and cycloalkyl; R,is a substituent of the general formula C,F,selected from the group consisting of the perfluoro-n-alkyl, perfluoro-sec-alkyl, perfluoro-tert-alkyl, and perfluorocycloalkyls, with the proviso that only one of R,and R,can be linear, and that n>3, the sum of n&plus;m<18 and that only either R,or R,are an n-alkyl or perfluorinated n-alkyl. These partially fluorinated alkanes find use as solvents, especially in medical applications where the properties of hydrocarbon solvents are not acceptable, in implants, and as an oxygen carrying blood substitute.

Growing community of inventors

Diedorf, Germany

Dirk-Henning Menz